SNDX
Syndax Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
13.65
close · 2026-10-30
value
25
cheaper than peers25
quality
22
stronger fundamentals22
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.83× | 70 |
| earnings yield, 3 years ago | -18.0% | 45 |
| earnings yield, 2 years ago | -21.8% | 44 |
| cash flow yield, 3 years ago | -11.0% | 43 |
| cash flow yield, 2 years ago | -13.2% | 41 |
| earnings yield, 1 year ago | -27.3% | 40 |
| earnings yield, latest year | -24.1% | 37 |
| cash flow yield, 1 year ago | -22.6% | 30 |
| cash flow yield, latest year | -26.5% | 28 |
| price to book | 80.77× | 3 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 91.8% | 76 |
| operating margin | -54.9% | 60 |
| return on equity | -255.9% | 9 |
| debt to equity | 3903.5% | 0 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | -$150.1M |
| employees | 298 |
| first trade | 2016-03-02 |
| next earnings | 2026-11-02 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.29 | -3.72 | -2.98 | -2.46 |
| free cash flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M |
| net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M |
| revenue | $172.4M | $23.7M | $0 | $0 |